BR112012033690A2 - sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos - Google Patents

sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos

Info

Publication number
BR112012033690A2
BR112012033690A2 BR112012033690A BR112012033690A BR112012033690A2 BR 112012033690 A2 BR112012033690 A2 BR 112012033690A2 BR 112012033690 A BR112012033690 A BR 112012033690A BR 112012033690 A BR112012033690 A BR 112012033690A BR 112012033690 A2 BR112012033690 A2 BR 112012033690A2
Authority
BR
Brazil
Prior art keywords
compounds
calcium salts
antitroliferative
immunomodular
antiinflammatory
Prior art date
Application number
BR112012033690A
Other languages
English (en)
Other versions
BR112012033690B1 (pt
Inventor
Aldo Ammendola
Daniel Vitt
Johann Leban
Julia Diederichs
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of BR112012033690A2 publication Critical patent/BR112012033690A2/pt
Publication of BR112012033690B1 publication Critical patent/BR112012033690B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Abstract

sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos. a presente invenção refere-se a sais de cálcio de compostos da fórmula geral (l) em que x é selecionado do grupo constindo em ch~ 2~ s ou d; d é o ou s; r^ 8^ é hidrogênio ou alquila; e é um grupo fenileno opcionalmente substituído; y é um sistema de anel de 6-9 menbros substituídos ou não substituído monocíclico ou bicíclico que pode conter um ou mais heteroátomos selecionados de n ou s e que contém pelo menos um anel aromático; n é 0 ou 1 e q é 0 ou 1; contando que os compostos em que x =ch~ 2~, q = 0, y= fenila são substituída e e = fenileno não substituído sejam excluídos; ou um hidrato do mesmo.
BR112012033690-8A 2010-07-01 2011-07-01 Sais de cálcio de compostos como agentes anti-inflamatórios, imunomoduladores e antiproliferativos, seu uso, seu processo de preparação e composição farmacêutica que os compreende BR112012033690B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36067010P 2010-07-01 2010-07-01
US61/360,670 2010-07-01
PCT/EP2011/061128 WO2012001148A1 (en) 2010-07-01 2011-07-01 Novel calcium salts of compound as anti-inflammatory, immunomodulatory and anti-proliferatory agents

Publications (2)

Publication Number Publication Date
BR112012033690A2 true BR112012033690A2 (pt) 2016-12-06
BR112012033690B1 BR112012033690B1 (pt) 2021-08-03

Family

ID=44584905

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033690-8A BR112012033690B1 (pt) 2010-07-01 2011-07-01 Sais de cálcio de compostos como agentes anti-inflamatórios, imunomoduladores e antiproliferativos, seu uso, seu processo de preparação e composição farmacêutica que os compreende

Country Status (24)

Country Link
US (2) US20120035175A1 (pt)
EP (3) EP2588447A1 (pt)
JP (2) JP2013531667A (pt)
KR (1) KR101906607B1 (pt)
CN (2) CN103038210B (pt)
AU (1) AU2011273409B2 (pt)
BR (1) BR112012033690B1 (pt)
CA (1) CA2804197C (pt)
DK (1) DK2966058T3 (pt)
EA (1) EA022462B1 (pt)
ES (1) ES2649732T3 (pt)
HK (1) HK1221213A1 (pt)
HU (1) HUE036287T2 (pt)
IL (1) IL223865B (pt)
ME (1) ME02939B (pt)
MX (1) MX2013000251A (pt)
NO (1) NO2966058T3 (pt)
NZ (1) NZ605010A (pt)
PL (1) PL2966058T3 (pt)
PT (1) PT2966058T (pt)
SG (1) SG186839A1 (pt)
UA (1) UA108760C2 (pt)
WO (2) WO2012001148A1 (pt)
ZA (1) ZA201300436B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108653260B (zh) * 2017-03-28 2023-03-21 厦门大学 一种法尼醇受体的配体的用途
WO2018177151A1 (en) * 2017-03-28 2018-10-04 Xiamen University Compounds modulating activity of farnesoid x receptor and methods for the use thereof
CN110251498A (zh) * 2018-03-12 2019-09-20 厦门大学 一类调节法尼醇受体活性的化合物及其用途
BR112020009477A2 (pt) * 2017-11-23 2020-11-03 Immunic Ag compostos e regime de dosagem para uso na prevenção ou tratamento de doenças inflamatórias e/ou autoimunes
SG11202008032YA (en) * 2018-03-16 2020-09-29 Immunic Ag Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP3750892A1 (en) 2019-06-14 2020-12-16 Yerevan State University Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
WO2021214033A1 (en) 2020-04-21 2021-10-28 Immunic Ag Vidofludimus for use in the treatment or prevention of viral diseases
WO2022214691A1 (en) 2021-04-09 2022-10-13 Immunic Ag Deuterated dhodh inhibitors
US11877994B2 (en) 2021-08-02 2024-01-23 Immunic Ag Treatment of multiple sclerosis comprising DHODH inhibitors
WO2023118576A1 (en) 2021-12-23 2023-06-29 Immunic Ag Dhodh inhibitors containing a carboxylic acid bioisostere
WO2023232884A1 (en) 2022-06-01 2023-12-07 Immunic Ag Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50121428A (pt) 1974-03-12 1975-09-23
NL186239B (nl) 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
IL56012A (en) 1977-11-29 1983-07-31 Takeda Chemical Industries Ltd N-(2-fluoro-4-bromo(or chloro)phenyl)-3,4,5,6-tetrahydrophthalamic acid derivatives,their preparation,and herbicidal compositions comprising them
JPS54154737A (en) 1978-05-25 1979-12-06 Mitsubishi Chem Ind Ltd Cyclohexenedicarboxylic acid diamide and herbicide
JPS55157547A (en) 1979-05-28 1980-12-08 Takeda Chem Ind Ltd Tetrahydrophthalamide derivative, its preparation and herbicide
AU1526483A (en) 1982-06-14 1983-12-22 Nippon Kayaku Kabushiki Kaisha N-substituted-3,4,5,6-tetrahydrophthalamic acids
JPS59118750A (ja) 1982-12-27 1984-07-09 Eisai Co Ltd カルボン酸アミド化合物およびその誘導体
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB9320299D0 (en) 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
WO1999038846A1 (en) 1998-01-30 1999-08-05 Procept, Inc. Immunosuppressive agents
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
MXPA04000224A (es) * 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
US7247736B2 (en) * 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
WO2010052027A1 (en) * 2008-11-07 2010-05-14 4Sc Ag Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease
TWI530286B (zh) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑

Also Published As

Publication number Publication date
PL2966058T3 (pl) 2018-06-29
CN103097338A (zh) 2013-05-08
WO2012001151A1 (en) 2012-01-05
AU2011273409A1 (en) 2013-01-31
CA2804197A1 (en) 2012-01-05
AU2011273409B2 (en) 2016-02-18
CA2804197C (en) 2018-09-18
SG186839A1 (en) 2013-02-28
CN103038210A (zh) 2013-04-10
EP2588447A1 (en) 2013-05-08
EA022462B1 (ru) 2016-01-29
IL223865B (en) 2018-04-30
NO2966058T3 (pt) 2018-03-03
JP2013531667A (ja) 2013-08-08
MX2013000251A (es) 2013-10-28
EP2966058A1 (en) 2016-01-13
US20120035175A1 (en) 2012-02-09
NZ605010A (en) 2014-08-29
HK1221213A1 (zh) 2017-05-26
DK2966058T3 (da) 2017-11-13
ME02939B (me) 2018-04-20
KR101906607B1 (ko) 2018-10-10
HUE036287T2 (hu) 2018-06-28
EA201291376A1 (ru) 2013-07-30
US8653138B2 (en) 2014-02-18
IL223865A0 (en) 2013-03-05
KR20130028973A (ko) 2013-03-20
JP2013531666A (ja) 2013-08-08
EP2588446B1 (en) 2015-09-09
BR112012033690B1 (pt) 2021-08-03
ZA201300436B (en) 2014-06-25
EP2588446A1 (en) 2013-05-08
PT2966058T (pt) 2017-11-09
UA108760C2 (uk) 2015-06-10
US20120029034A1 (en) 2012-02-02
EP2966058B1 (en) 2017-10-04
CN103038210B (zh) 2015-06-10
JP5819954B2 (ja) 2015-11-24
WO2012001148A1 (en) 2012-01-05
ES2649732T3 (es) 2018-01-15

Similar Documents

Publication Publication Date Title
BR112012033690A2 (pt) sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos
BR112012033350A2 (pt) "composição e métodos para modular a via de sinalização de wnt"
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
BR112012026950A2 (pt) composto, e, uso de um composto
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
NI201000120A (es) Derivados de ftalazinona
UY34177A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
EA201170772A1 (ru) Органические соединения
EA201171004A1 (ru) Пиридазиноновые соединения
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
BR112015016310A2 (pt) método para controlar peste artrópode
BR112015018509A2 (pt) compostos de imidazo piridina
BR112013008675A2 (pt) métodos e composições para o tratamento de diabetes e dislipidemia
EA201490438A1 (ru) Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные циклопента[c]пирролом
BR112012021135A2 (pt) microbicidas
EA201170074A1 (ru) Изохинолиноновые производные в качестве антагонистов nk3
AR098269A1 (es) Poliéster terminado en epoxi
BR112015006370A2 (pt) meios e métodos para tratamento de tumores sólidos
BR112014026082A2 (pt) composto, e, método para marcar um hidrocarboneto de petróleo ou um combustível líquido derivado biologicamente
BR112013005823B8 (pt) Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina
EA201690924A1 (ru) Фторфенилпиразольные соединения
EA201370251A1 (ru) Производное камптотецина, способ получения такового, фармацевтическая композиция и ее применение
BR112015009988A2 (pt) melhoramentos em compostos orgânicos ou relativos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.